Valuation dashboard for MBX Biosciences, Inc. Common Stock (MBX) with P/E N/A, P/B 6.41, EV/EBITDA -23.8 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $55.00 (closing price, November 3, 2026), MBX has negative trailing earnings (P/E not meaningful) and an ROE of -26.01%. Market capitalisation stands at $2.6B.
Balance sheet quality for MBX: debt-to-equity ratio of 0.01, current ratio of 18.08 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 6.41 |
| EV / EBITDA | -23.8 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. Common Stock | $2.6B | 6.41 | -26.0% | |
| ASND | Ascendis Pharma A/S | $16.5B | 18.46 | 10.01 | 190.4% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $6.0B | 29.61 | -83.7% | |
| VKTX | Viking Therapeutics, Inc. | $3.3B | 5.23 | -117.3% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.96 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 13.38 | -39.2% |
Price
| Price | $55.00 (closing price, November 3, 2026) |
| Market Cap | $2.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -26.01% |
| Return on Invested Capital | -28.56% |
| Return on Assets | -23.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ASND · RYTM · VKTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of MBX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks